No Data
No Data
Investors who bought high-level pharmaceutical Funds have hope! More than 80% of products achieved positive returns in the first quarter, and recovering losses is promising.
① A total of 264 medical Funds had positive returns in the first quarter of this year, accounting for over 80%, with many Funds achieving returns exceeding 15% this year. ② The net value of medical Funds established in 2020 and 2021 is currently being repaired, and investors who entered at high levels are expected to break even.
The annual loss of Aimee Vaccine (06660.HK) narrowed to 0.277 billion yuan.
Aimee Vaccine (06660.HK) announced its annual results for 2024, with revenue recording 1.285 billion RMB, an increase of 8.2% year-on-year. Loss narrowed from 1.301 billion last year to 0.277 billion, with a loss per share of 23 cents. No final dividend is declared.
Aimee Vaccine (06660) achieved revenue of approximately 1.285 billion yuan in 2024, an 8.2% year-on-year growth, with comprehensive breakthroughs in the innovative pipeline.
Aimee Vaccine (06660) announced its 2024 performance, with revenue of approximately 1.285 billion yuan, a year-on-year increase of 8.2%. ...
AIM VACCINE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
AIM Gets US FDA Clinical Trial Approval for Herpes Zoster Vaccine; Shares Up 8%
A new major product from Aimee (06660), the mRNA shingles vaccine, has been approved by the FDA in the USA to carry out clinical trials.
Aimee Vaccine (06660) announced on March 23 that the mRNA shingles vaccine has recently obtained clinical trial permission from the FDA.